Overview
Influenza is an acute respiratory infection caused by influenza viruses, leading to significant morbidity and mortality worldwide, particularly among high-risk populations such as the elderly, young children, and individuals with chronic health conditions 19.Diagnosis
Management
Special Populations
Key Recommendations
References
Showing 100 most recent of 850 indexed papers.
1 Vandvik PO, Agarwal A, Rylance J, Agoritsas T, Guyatt G, Leo YS et al.. Summary of WHO clinical practice guidelines for influenza. BMJ (Clinical research ed.) 2026. link 2 Rosu ME, Westgeest KB, de Graaf M, Hauser BM, Tureli S, James S et al.. Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase. Cell host & microbe 2026. link 3 Kamyshnyi O, Halabitska I, Oksenych V, Kamyshna I, Petakh P, Kainov DE. Forecasting Influenza Epidemics and Pandemics in the Age of AI and Machine Learning. Reviews in medical virology 2026. link 4 Wang L, Salje H. Scaling up efforts to target evolving viruses. eLife 2026. link 5 Yang Z, Li Y, Chen L, Jia S. Designing a broad-spectrum multi-epitope vaccine against influenza A and . Frontiers in public health 2026. link 6 Tu Y, Lai X, Wan Q, Xu T. Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database. Expert opinion on drug safety 2026. link 7 . Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Policy Statement. Pediatrics 2025. link 8 . Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Technical Report. Pediatrics 2025. link 9 Meixner J, Nußbaumer-Streit B, Sommer I. [WHO clinical practice guidelines for influenza: an update]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) 2025. link 10 Alvarez Aldeán J, Alvarez García FJ, Cruz Cañete M, Fernández Prada M, Francisco González L, Grande Tejada AM et al.. Seasonal influenza vaccination in childhood and adolescence. Consensus of the AEV, CAV-AEP and SEIP. Anales de pediatria 2025. link 11 Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X et al.. Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. JAMA internal medicine 2025. link 12 Monto AS, Kuhlbusch K, Bernasconi C, Cao B, Cohen HA, Graham E et al.. Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza. The New England journal of medicine 2025. link 13 Soens M, Ananworanich J, Hicks B, Lucas KJ, Cardona J, Sher L et al.. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine 2025. link 14 Presa J, Arranz-Herrero J, Alvarez-Losa L, Rius-Rocabert S, Pozuelo MJ, Lalueza A et al.. Influenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention. European respiratory review : an official journal of the European Respiratory Society 2025. link 15 Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS et al.. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. The New England journal of medicine 2025. link 16 Rudman Spergel AK, Lee IT, Koslovsky K, Schaefers K, Avanesov A, Logan DK et al.. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. Nature communications 2025. link 17 Fitz-Patrick D, McVinnie DS, Jackson LA, Crowther G, Geevarughese A, Cannon KD et al.. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. The New England journal of medicine 2025. link 18 Bonduelle O, Delory T, Franco-Moscardini I, Ghidi M, Bennacer S, Wokam M et al.. Boosting effect of high-dose influenza vaccination on innate immunity among elderly. JCI insight 2025. link 19 Viviani L, Vecchio R, Pariani E, Sandri L, Binda S, Ammoni E et al.. Wastewater-based epidemiology of influenza viruses: a systematic review. The Science of the total environment 2025. link 20 Bertrand SF, Kok G, Mafi A, Ruiter RAC, Ten Hoor GA. Interventions targeting healthcare worker influenza vaccination: A systematic review. Human vaccines & immunotherapeutics 2025. link 21 El Sahly HM, Anderson EJ, Jackson LA, Neuzil KM, Atmar RL, Bernstein DI et al.. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine 2025. link 22 Yegorov S, Brewer A, Cyr L, Ward BJ, Pullenayegum E, Miller MS et al.. Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children. The Journal of infectious diseases 2025. link 23 Ananworanich J, Lee IT, Ensz D, Carmona L, Schaefers K, Avanesov A et al.. Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial. The Journal of infectious diseases 2025. link 24 Wong WT, Choi G, Wang X, Wu WKK, Lin G, Chan MCW et al.. Pharmacodynamic Effect of Different Dosage Regimes of Oseltamivir in Severe Influenza Patients Requiring Mechanical Ventilation: A Multicentre Randomised Controlled Trial. Influenza and other respiratory viruses 2025. link 25 Kandinov B, Soens M, Huang W, Llapur C, Ensz D, Essink B et al.. An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. Human vaccines & immunotherapeutics 2025. link 26 Jiang L, Zhao J, Jin H. Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model-based meta-analysis. Human vaccines & immunotherapeutics 2025. link 27 Thistlethwaite W, Vangeti S, Cheng WS, Agarwal P, Cappuccio A, Wang W et al.. Innate immune molecular landscape following controlled human influenza virus infection. Cell reports 2025. link 28 Su A, Yan M, Herrler G, Becher P. Efficient replication of avian, porcine and human influenza A viruses in well-differentiated bovine airway epithelial cells. Emerging microbes & infections 2025. link 29 Kuchinski KS, Tyson J, Lee T, Detmer S, Berhane Y, Burns T et al.. Detection of a Reassortant Swine- and Human-Origin H3N2 Influenza A Virus in Farmed Mink in British Columbia, Canada. Zoonoses and public health 2025. link 30 Jing S, Wang H. Infectivity and fatality of influenza in pre- and post-COVID-19 pandemic year. PLoS computational biology 2025. link 31 Youhanna J, Puig-Barberà J, Miller MS, Molrine D, Hadi M, Bapat S et al.. Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study. BMC infectious diseases 2025. link 32 Jiménez-Juárez RN, Moreno-Espinosa S, Reyes-Lopez A, Parra-Ortega I, Laris-Gonzalez A, De la Rosa-Zamboni D et al.. Impact of Influenza on Children in a Referral Hospital in Mexico City: Clinical Burden and Predictors of Mechanical Ventilation. Viruses 2025. link 33 Davido B. The Unprecedented Influenza Epidemic of 2024/2025: Overshadowing the COVID-19 Winter Wave and Exploring Viral Interference. Immunity, inflammation and disease 2025. link 34 Sorrell EM, Kromm M, Gronvall G, Pekosz A, Davis MF. The consequences of letting avian influenza run rampant in US poultry. Science (New York, N.Y.) 2025. link 35 Djaló S, Tivane A, Nguenha N, Nascimento N, Banze Á, Rossetto É et al.. The influenza virus sentinel surveillance: results of system evaluation in Mozambique, 2016-2021. The Pan African medical journal 2025. link 36 Scheftel JM, Schenk KE, Bauck LJ, Bye ML, Ireland MJ, Klumb CA et al.. Human Health Surveillance During Animal Disease Emergencies: Minnesota Department of Health Response to Highly Pathogenic Avian Influenza Outbreaks, 2015 and 2022-2023. Journal of agromedicine 2025. link 37 Samantaray M, Pushan SS, Rajagopalan M, Abrol K, Basumatari J, Murthy TPK et al.. Designing a multi-epitope vaccine candidate against pandemic influenza a virus: an immunoinformatics and structural vaccinology approach. Molecular diversity 2025. link 38 Wagoner ZW, Yates TB, Hernandez-Davies JE, Sureshchandra S, Joloya EM, Jain A et al.. Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. Cell stem cell 2025. link 39 Zhou J, Ye J, Chen M, Zheng X. A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data. Expert opinion on drug safety 2025. link 40 Amaral de Avila Machado M, Gallo S, Goldstein A, Vachhani P, Byrareddy RM, Kantele A et al.. Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season. Human vaccines & immunotherapeutics 2025. link 41 Wu H, He X, Cao Y, Gao W. Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis. PloS one 2025. link 42 Grasty MA, L'Etoile N, Nitsche LJ, Takeda M, Fisher BT, Drant S et al.. Aortic Rupture in a Pediatric Patient With Influenza. World journal for pediatric & congenital heart surgery 2025. link 43 Skaarup KG, Davidovski FS, Durukan E, Modin D, Lassen MCH, Dons M et al.. Cardiac Characteristics of Hospitalized Influenza Patients: An Interim Analysis From the FluHeart Study. Influenza and other respiratory viruses 2025. link 44 Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2024. link 45 . Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Policy Statement. Pediatrics 2024. link 46 . Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Technical Report. Pediatrics 2024. link 47 Froes F, Timóteo A, Almeida B, Raposo JF, Oliveira J, Carrageta M et al.. Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine. Pulmonology 2024. link 48 Zhao Y, Gao Y, Guyatt G, Uyeki TM, Liu P, Liu M et al.. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet (London, England) 2024. link01357-6) 49 Gao Y, Guyatt G, Uyeki TM, Liu M, Chen Y, Zhao Y et al.. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet (London, England) 2024. link01307-2) 50 Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis. JAMA internal medicine 2024. link 51 Shiraishi C, Kato H, Hagihara M, Asai N, Iwamoto T, Mikamo H. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2024. link 52 Alam MM, Paul T, Aggarwal A, Zarich S. Influenza associated cardiac arrhythmia- a systematic review. The American journal of the medical sciences 2024. link 53 Ferdinands JM, Blanton LH, Alyanak E, Chung JR, Trujillo L, Taliano J et al.. Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: A systematic review and network meta-analysis. Journal of the American Geriatrics Society 2024. link 54 Skaarup KG, Lassen MCH, Modin D, Johansen ND, Loiacono MM, Harris RC et al.. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials. The Journal of infection 2024. link 55 Lu LY, Lee HM, Burke A, Li Bassi G, Torres A, Fraser JF et al.. Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Systematic Review and Meta-Analysis. Chest 2024. link 56 Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A et al.. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein. EBioMedicine 2024. link 57 Beishuizen BHH, Stein ML, Buis JS, Tostmann A, Green C, Duggan J et al.. A systematic literature review on public health and healthcare resources for pandemic preparedness planning. BMC public health 2024. link 58 Li F, Sun Z, Tao M, Song K, Wang Z, Ren X. Epidemiological characterization of human infection with H5N6 avian influenza. Frontiers in public health 2024. link 59 Zhong S, Ng TWY, Skowronski DM, Iuliano AD, Leung NHL, Perera RAPM et al.. Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status. The Journal of infectious diseases 2024. link 60 Pittman Ratterree DC, Dass SC, Ndeffo-Mbah ML. Mechanistic Models of Influenza Transmission in Commercial Swine Populations: A Systematic Review. Pathogens (Basel, Switzerland) 2024. link 61 Bernasconi C, Katugampola L, Wildum S. Comparison of influenza viral load in nasopharyngeal and midturbinate swabs. Influenza and other respiratory viruses 2024. link 62 Dlamini M, Msolo L, Ehi Ebomah K, Nontongana N, Ifeanyi Okoh A. A systematic review on the incidence of influenza viruses in wastewater matrices: Implications for public health. PloS one 2024. link 63 Nauta J. Estimand for non-inferiority influenza vaccine immunogenicity trials. Vaccine 2024. link 64 Motaghi S, Pullenayegum E, Morgan RL, Loeb M. The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children. Vaccine 2024. link 65 Álvarez Aldeán J, Álvarez García FJ, Garcés-Sánchez M, Garrote Llanos E, Iofrío de Arce A, Navarro Gómez ML et al.. Vaccination against seasonal flu in childhood and adolescence. Recommendations of the Advisory Committee on Vaccines and Immunizations of the Spanish Association of Pediatrics (CAV-AEP) for the 2024-2025 season. Anales de pediatria 2024. link 66 Garai R, Jánosi Á, Krivácsy P, Herczeg V, Kói T, Nagy R et al.. Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis. Journal of translational medicine 2024. link 67 Bi Y, Yang J, Wang L, Ran L, Gao GF. Ecology and evolution of avian influenza viruses. Current biology : CB 2024. link 68 Studniski M, Stumvoll K, Kromm M, Ssematimba A, Marusak R, Xing Z et al.. Vaccination of Poultry Against Influenza. Avian diseases 2024. link 69 Marchenko VA, Zhilinskaya IN. Endothelial activation and dysfunction caused by influenza A virus (. Voprosy virusologii 2024. link 70 Waldock J, Cox RJ, Chiu C, Subbarao K, Wildfire A, Barclay W et al.. Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK. Influenza and other respiratory viruses 2024. link 71 Kristensen C, Jensen HE, Trebbien R, Webby RJ, Larsen LE. Avian and Human Influenza A Virus Receptors in Bovine Mammary Gland. Emerging infectious diseases 2024. link 72 Serafin B, Kamen A, de Crescenzo G, Henry O. Antibody-independent surface plasmon resonance assays for influenza vaccine quality control. Applied microbiology and biotechnology 2024. link 73 Yang Q, Park SW, Saad-Roy CM, Ahmad I, Viboud C, Arinaminpathy N et al.. Assessing population-level target product profiles of universal human influenza A vaccines. Epidemics 2024. link 74 Lane MC, Luke CJ, Bresee J, Dugan VG, Post DJ, Schafer J et al.. Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation. Influenza and other respiratory viruses 2024. link 75 Thompson AJ, Wu NC, Canales A, Kikuchi C, Zhu X, de Toro BF et al.. Evolution of human H3N2 influenza virus receptor specificity has substantially expanded the receptor-binding domain site. Cell host & microbe 2024. link 76 Juárez X, García Causarano MF, Burundarena C, Dondoglio P, Montoto Piazza L, Wenk G et al.. Children with influenza admitted at a children's hospital in Argentina in the 2019-2022 period: What has changed after the COVID-19 pandemic?. Archivos argentinos de pediatria 2024. link 77 Whitaker H, Findlay B, Zitha J, Goudie R, Hassell K, Evans J et al.. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom. Influenza and other respiratory viruses 2024. link 78 Le Sage V, Campbell AJ, Reed DS, Duprex WP, Lakdawala SS. Persistence of Influenza H5N1 and H1N1 Viruses in Unpasteurized Milk on Milking Unit Surfaces. Emerging infectious diseases 2024. link 79 Daulagala P, Cheng SMS, Chin A, Luk LLH, Leung K, Wu JT et al.. Avian Influenza A(H5N1) Neuraminidase Inhibition Antibodies in Healthy Adults after Exposure to Influenza A(H1N1)pdm09. Emerging infectious diseases 2024. link 80 Unione L, Ammerlaan ANA, Bosman GP, Uslu E, Liang R, Broszeit F et al.. Probing altered receptor specificities of antigenically drifting human H3N2 viruses by chemoenzymatic synthesis, NMR, and modeling. Nature communications 2024. link 81 Bialy D, Richardson S, Chrzastek K, Bhat S, Polo N, Freimanis G et al.. Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo. Virology 2024. link 82 Rabeeah I, Billington E, Nal B, Sadeyen JR, Pathan AA, Iqbal M et al.. Mapping the interaction sites of human and avian influenza A viruses and complement factor H. Frontiers in immunology 2024. link 83 Mills G. Avian flu causes concerning falls in seabird numbers. The Veterinary record 2024. link 84 Stefania C, Alessio M, Paolo M, Tiziano D, Favretto AR, Francesca Z et al.. The application of biosecurity practices for preventing avian influenza in North-Eastern Italy turkey farms: An analysis of the point of view and perception of farmers. Preventive veterinary medicine 2024. link 85 Prada GI, Băjenaru OL, Chelu GC, Matei-Lincă CM, Nuţă CR, Moscu SG. Protecting the elderly from influenza in the context of immune system senescence. Elderly aged 65 and over are vulnerable to influenza and its associated complications.: Position paper by the Romanian Society of Gerontology and Geriatrics. Journal of medicine and life 2024. link 86 Momajadi L, Khanahmad H, Mahnam K. Designing a multi-epitope influenza vaccine: an immunoinformatics approach. Scientific reports 2024. link 87 Ghafoor D, Zeb A, Ali SS, Ali M, Akbar F, Ud Din Z et al.. Immunoinformatic based designing of potential immunogenic novel mRNA and peptide-based prophylactic vaccines against H5N1 and H7N9 avian influenza viruses. Journal of biomolecular structure & dynamics 2024. link 88 Chen F, Chen Y, Liang H, Pan X, Wang Y, Shen L et al.. Non-linear effects of age in reporting of adverse events following influenza immunization in Zhejiang, China. BMC infectious diseases 2024. link 89 Sarker J, Carkovic E, Ptaszek K, Lee TA. Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Pharmacotherapy 2024. link 90 de la Cueva IS, Gerber JE, Hastie A, Brotons C, Panzer F, Pirçon JY et al.. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season. Drug safety 2024. link 91 Li Y, Wang X, Liao Y, Zeng Y, Lin W, Zhuang W. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system. BMC infectious diseases 2024. link 92 Zhou Y, Jin L, Lai X, Li Y, Sheng L, Xie G et al.. Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: A pharmacovigilance study using the FAERS database. PloS one 2024. link 93 Li Y, Li J, He J, Tao C. AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events. PloS one 2024. link 94 Ouranos K, Vassilopoulos S, Vassilopoulos A, Shehadeh F, Mylonakis E. Cumulative incidence and mortality rate of cardiovascular complications due to laboratory-confirmed influenza virus infection: A systematic review and meta-analysis. Reviews in medical virology 2024. link 95 . Recommendations for Prevention and Control of Influenza in Children, 2023-2024. Pediatrics 2023. link 96 . Recommendations for Prevention and Control of Influenza in Children, 2023-2024. Pediatrics 2023. link 97 Westin J, Andersson E, Bengnér M, Berggren A, Brytting M, Ginström Ernstad E et al.. Management of influenza - updated Swedish guidelines for antiviral treatment. Infectious diseases (London, England) 2023. link 98 Arranz-Herrero J, Presa J, Rius-Rocabert S, Utrero-Rico A, Arranz-Arija JÁ, Lalueza A et al.. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023. link 99 Yang D, Huang L, Wang J, Wu H, Liu Z, Abudureyimu A et al.. Tumorigenesis mechanism and application strategy of the MDCK cell line: A systematic review. Biologicals : journal of the International Association of Biological Standardization 2023. link 100 Yu LJ, Li XL, Wang YH, Zhang HY, Ruan SM, Jiang BG et al.. Short-Term Exposure to Ambient Air Pollution and Influenza: A Multicity Study in China. Environmental health perspectives 2023. link